Targeted cancer therapeutics: the heartbreak of success

Tyrosine kinase inhibitors, widely hailed for their success as treatments for cancer, are also plagued by the issue of cardiotoxic side effects. The mechanism behind the heart damage now comes to light for one such inhibitor, imatinib mesylate, also known as Gleevec (pages 908916).

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Sustained endoplasmic reticulum stress can lead to apoptosis through several pathways.

Kim Caesar

References

  1. 1

    Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).

  2. 2

    Crone, S.A. et al. Nat. Med. 8, 459–465 (2002).

  3. 3

    Kerkelä, R. et al. Nat. Med. 12, 908–916 (2006).

  4. 4

    Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).

  5. 5

    Terai, K. et al. Mol. Cell Biol. 25, 9554–9575 (2005).

  6. 6

    Boyce, M. & Yuan, J. Cell Death. Differ. 13, 363–373 (2006).

  7. 7

    Kumar, S. et al. J. Biol. Chem. 276, 17281–17285 (2001).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading